BioAffinity says CyPath Lung test unit sales achieved monthly record in April

BioAffinity Technologies (BIAF) announced that unit sales for its CyPath Lung diagnostic test achieved a record high in a single month and increased nearly 300% in April 2026 compared to the same period in 2025, based on preliminary unaudited data. The strong CyPath Lung unit sales growth so far this year continues to exceed the Company’s internal projections and reflects accelerating physician adoption and expanding clinical use by physicians using the Company’s noninvasive test to aid in diagnosing lung cancer, the company said. “The growth in CyPath(R) Lung usage continues to accelerate at a rapid pace as the value of our novel lung cancer diagnostic is increasingly being recognized,” said Maria Zannes, President and CEO of bioAffinity Technologies. “CyPath(R) Lung addresses a significant gap in the diagnostic pathway by supporting lung cancer risk stratification and pulmonary nodule management as physicians seek more accurate, noninvasive tools to assess cancer risk and detect disease at its earliest, most treatable stage. We are very pleased with the unit growth that we delivered in April, and we remain focused on expanding adoption of CyPath(R) Lung to aid physicians in the early detection of lung cancer and pulmonary nodule management.”